Stephanie A. Schultz,Zahra Shirzadi,Aaron P. Schultz,Lei Liu,Colleen D. Fitzpatrick,Eric McDade,Nicolas R. Barthelemy,Alan Renton,Bianca Esposito,Nelly Joseph‐Mathurin,Carlos Cruchaga,Charles D. Chen,Alison Goate,Ricardo Francisco Allegri,Tammie L. S. Benzinger,Sarah Berman,Helena C. Chui,Anne M. Fagan,Martin R. Farlow,Nick C. Fox,Brian A. Gordon,Gregory S. Day,Neill R. Graff‐Radford,Jason J. Hassenstab,Bernard J. Hanseeuw,Anna Hofmann,Clifford R. Jack,Mathias Jucker,Celeste M. Karch,Robert A. Koeppe,Jae‐Hong Lee,Allan I. Levey,Johannes Levin,Ralph N. Martins,Hiroshi Mori,John C. Morris,James Noble,Richard J. Perrin,Pedro Rosa‐Neto,Stephen P. Salloway,Raquel Sanchez‐Valle,Peter R. Schofield,Chengjie Xiong,Keith A. Johnson,Randall J. Bateman,Reisa A. Sperling,Jasmeer P. Chhatwal,the Dominantly Inherited Alzheimer Network Investigators

Abstract:Although pathogenic variants in PSEN1 leading to autosomal‐dominant Alzheimer disease (ADAD) are highly penetrant, substantial interindividual variability in the rates of cognitive decline and biomarker change are observed in ADAD. PSEN1 variant carriers participating in the Dominantly Inherited Alzheimer Network were grouped based on whether the underlying variant affects a transmembrane (TM) or cytoplasmic (CY) protein domain within PSEN1. While both CY and TM groups were found to have similarly elevated beta‐amyloid burden compared to non‐carriers, TM carriers had greater cognitive impairment, smaller hippocampal volume, and elevated phosphorylated tau levels compared to CY carriers. Although pathogenic variants in PSEN1 leading to autosomal‐dominant Alzheimer disease (ADAD) are highly penetrant, substantial interindividual variability in the rates of cognitive decline and biomarker change are observed in ADAD. We hypothesized that this interindividual variability may be associated with the location of the pathogenic variant within PSEN1. PSEN1 pathogenic variant carriers participating in the Dominantly Inherited Alzheimer Network (DIAN) observational study were grouped based on whether the underlying variant affects a transmembrane (TM) or cytoplasmic (CY) protein domain within PSEN1. CY and TM carriers and variant non‐carriers (NC) who completed clinical evaluation, multimodal neuroimaging, and lumbar puncture for collection of cerebrospinal fluid (CSF) as part of their participation in DIAN were included in this study. Linear mixed effects models were used to determine differences in clinical, cognitive, and biomarker measures between the NC, TM, and CY groups. While both the CY and TM groups were found to have similarly elevated Aβ compared to NC, TM carriers had greater cognitive impairment, smaller hippocampal volume, and elevated phosphorylated tau levels across the spectrum of pre‐symptomatic and symptomatic phases of disease as compared to CY, using both cross‐sectional and longitudinal data. As distinct portions of PSEN1 are differentially involved in APP processing by γ‐secretase and the generation of toxic β‐amyloid species, these results have important implications for understanding the pathobiology of ADAD and accounting for a substantial portion of the interindividual heterogeneity in ongoing ADAD clinical trials.

Alteration of gene expression and protein solubility of the PI 5-phosphatase SHIP2 are correlated with Alzheimer's disease pathology progression

Inpp5d Deficiency Exacerbates Tau Pathology and Cognitive Deficits in MAPTP301S Mouse

INPP5D limits plaque formation and glial reactivity in the APP/PS1 mouse model of Alzheimer’s disease

Discovery and evaluation of novel SHIP-1 inhibitors

Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease

Altered Expression Profile of Phosphatidylinositols in Erythrocytes of Alzheimer's Disease and Amnestic Mild Cognitive Impairment Patients.

Genetic Dissection of Glutathione S-transferase Omega-1: Identification of Novel Downstream Targets and Alzheimer’s Disease Pathways

Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism

Neuronal downregulation of impairs synaptic function and elicits Alzheimer disease hallmarks

Dysregulated expression of cholesterol biosynthetic genes in Alzheimer's disease alters epigenomic signatures of hippocampal neurons

CYP1B1 - RMDN2 Alzheimer's disease endophenotype locus identified for cerebral tau PET

CD33 and SHP-1/PTPN6 Interaction in Alzheimer's Disease

Targeted Genetic Analysis of Cerebral Blood Flow Imaging Phenotypes Implicates the INPP5D Gene.

Location of pathogenic variants in PSEN1 impacts progression of cognitive, clinical, and neurodegenerative measures in autosomal‐dominant Alzheimer's disease

Microglial INPP5D Limits Plaque Formation and Glial Reactivity in the PSAPP Mouse Model of Alzheimer's Disease

SHIP1 modulation and proteome characterization of microglia

Impact of APOE ε4 and ε2 on plasma neurofilament light chain and cognition in autosomal dominant Alzheimer's disease

Genome-wide analysis identifies a novel LINC-PINT splice variant associated with vascular amyloid pathology in Alzheimer’s disease

Mutations in PSEN1 predispose inflammation in an astrocyte model of familial Alzheimer's disease through disrupted regulated intramembrane proteolysis

Two Novel Pde11a Genetic Variants Increase Tau Phosphorylations in Early-onset Alzheimer's Disease

Xenografted human iPSC-derived neurons with the familial Alzheimer's disease APPV717I mutation reveal dysregulated transcriptome signatures linked to synaptic function and implicate LINGO2 as a disease signaling mediator